Abstract
Alzheimer’s disease (AD) remains a major health problem, and accounts for 50 to 60% of all cases of dementia. The two histopathological hallmarks of AD are senile plaques, composed of the β-amyloid peptide (Aβ), and intraneuronal neurofibrillary tangles composed of abnormally hyperphosphorylated tau protein. Only a small proportion of AD is due to mutations in the genome of patients, the large majority of cases being of late onset and sporadic in origin. The relative contribution of genetics and environment to the sporadic cases is unclear, but they are accepted to be of multifactorial origin. This means that genetic and environmental factors can interact together to induce or accelerate the disease. Among environmental factors, studies suggest that hypothermia may contribute to the development and exacerbation AD. Here, we review the preclinical data involving hypothermia with tau and Aβ, as well as clinical evidence implicating hypothermia in the development of AD. Keywords: Alzheimer’s dementia, tau, beta
Keywords: Alzheimer’s dementia, tau, beta-amyloid, phosphorylation, hypothermia, PP2A, phosphatases.
Current Alzheimer Research
Title:Hypothermia and Alzheimer's Disease Neuropathogenic Pathways
Volume: 7 Issue: 8
Author(s): R. A. Whittington, M.-A. Papon, F. Chouinard-Decorte and E. Planel
Affiliation:
Keywords: Alzheimer’s dementia, tau, beta-amyloid, phosphorylation, hypothermia, PP2A, phosphatases.
Abstract: Alzheimer’s disease (AD) remains a major health problem, and accounts for 50 to 60% of all cases of dementia. The two histopathological hallmarks of AD are senile plaques, composed of the β-amyloid peptide (Aβ), and intraneuronal neurofibrillary tangles composed of abnormally hyperphosphorylated tau protein. Only a small proportion of AD is due to mutations in the genome of patients, the large majority of cases being of late onset and sporadic in origin. The relative contribution of genetics and environment to the sporadic cases is unclear, but they are accepted to be of multifactorial origin. This means that genetic and environmental factors can interact together to induce or accelerate the disease. Among environmental factors, studies suggest that hypothermia may contribute to the development and exacerbation AD. Here, we review the preclinical data involving hypothermia with tau and Aβ, as well as clinical evidence implicating hypothermia in the development of AD. Keywords: Alzheimer’s dementia, tau, beta
Export Options
About this article
Cite this article as:
A. Whittington R., Papon M.-A., Chouinard-Decorte F. and Planel E., Hypothermia and Alzheimer's Disease Neuropathogenic Pathways, Current Alzheimer Research 2010; 7 (8) . https://dx.doi.org/10.2174/156720510793611646
DOI https://dx.doi.org/10.2174/156720510793611646 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Neurotrophin Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease
Current Pharmaceutical Design Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Topics in Medicinal Chemistry Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Properties and Clinical Development of a Novel Coating Technology: The poly[bis(trifluoroethoxy)phosphazene]
Recent Patents on Drug Delivery & Formulation Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Properties and Therapeutic Potential of Transient Receptor Potential Channels with Putative Roles in Adversity: Focus on TRPC5, TRPM2 and TRPA1
Current Drug Targets Small Molecule TGF-beta Mimetics as Potential Neuroprotective Factors
Current Alzheimer Research Preface [Hot Topic: Current Trends in the Development of Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents (Executive Editors: P. Camps and D. Munoz-Torrero)]
Current Pharmaceutical Design APP Transgenic Mouse Models and their Use in Drug Discovery to Evaluate Amyloid-β Lowering Therapeutics
CNS & Neurological Disorders - Drug Targets To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Blood-Brain-Barrier Models for the Investigation of Transporter- and Receptor-Mediated Amyloid-β Clearance in Alzheimers Disease
Current Alzheimer Research Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Ligand and Structure-Based Drug Design as Strategies for the Screening of New BACE1 Inhibitor Candidates
Current Physical Chemistry Antifungal Activity of 3-(heteroaryl-2-ylmethyl)thiazolidinone Derivatives
Medicinal Chemistry Predicted Fold for the Abri Amyloid Subunit: A Model for Amyloidogenesis in Familial British Dementia
Protein & Peptide Letters Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain
Current Alzheimer Research Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Acute Symptomatic Seizures in Geriatric Patients with Multiple Risk Factors - A Diagnostic Challenge
Current Aging Science